Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105645 | 0.77 | USP8 (0.33) | ALDH1A1LMNAMEN1KMT2ATRPA1 | |
| SCHEMBL10120883 | 0.75 | HSD17B10 (0.39) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL13038361 | 0.74 | LMNA (0.39) | ALDH1A1LMNAHPGDTRPA1CHRM1 | |
| SCHEMBL13437803 | 0.74 | GABRA1 (0.48) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL12305725 | 0.74 | ALDH1A1 (0.43) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL11339660 | 0.74 | TRPV4 (0.41) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| Ethane SCHEMBL2154081 | 0.73 | GABRA1 (0.46) | ALDH1A1KDM4ELMNAHPGDSLC6A2 | |
| SCHEMBL12992602 | 0.73 | LMNA (0.38) | ALDH1A1LMNAHPGDTRPA1CHRM1 | |
| SCHEMBL9575176 | 0.72 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL22251909 | 0.72 | CYP1A2 (0.35) | ALDH1A1KDM4ELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | ALDH1A1 1743/4885KDM4E 3379/4885LMNA 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.